Laura Campbell Named to Medical News InCharge Healthcare

Ms. Campbell was once again named to this prestigious list of industry movers and shakers.

Says Medical News, “Nashville healthcare insider Laura Campbell has more than two decades of experience in the local healthcare and venture capital industries and has assisted more than 250 new ventures and existing businesses in their growth and development. Prior to launching her consulting firm in 1997, she founded the Nashville Health Care Council and served as partner for Massey Burch Capital Corp. Earlier in her career, she directed investor relations, marketing and public relations for Wessex Corp., a publicly traded healthcare company.”

DiaTech Oncology to Invest $2.7 Million to Expand Franklin, TN Operations Creating 39 New Jobs

Tennessee Economic and Community Development Commissioner Bill Hagerty along with DiaTech Oncology officials announced today the company will expand operations in Franklin, Tenn. DiaTech’s investment of $2.7 million will create 39 new positions over the next two years in Williamson County.

“Tennessee is a top state when it comes to research and development expenditures, and we are focused on leveraging our remarkable R&D assets, along with our strengths in the health care industry, to attract innovative companies like DiaTech to locate and expand in our state,” Hagerty said. “I appreciate DiaTech for their investment in Williamson County that will not only benefit our citizens and economy, but cancer patients and physicians worldwide.”

“DiaTech is pleased to begin its first U.S. laboratory operation in Franklin, Tennessee,” DiaTech Oncology President Garry Latimer said. “This laboratory is under development with a planned opening of its specialized ‘Correct Chemo Assay’ cancer testing facility in early 2014.”

“DiaTech’s test is the only test on the market that reveals to the treating oncologist the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient. As our clinical studies show, DiaTech’s test can guide therapy in individual patients,” DiaTech Oncology Chief Medical Officer Cary Presant, M.D., said.

Offering patient-specific chemotherapy testing, DiaTech helps oncologists determine the best cancer treatment plans for their patients. The company uses a patented technology called Microculture Kinetic (MiCK) assay which measures cell death induced in a specific patient’s cancer cells by chemotherapy. The analysis, which has been used successfully in more than 50 different tumor types, is the only test on the market that evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective.

“I am thrilled DiaTech has selected Williamson County as the location for their first U.S. lab operation in the United States,” Williamson County Mayor Rogers Anderson said. “Williamson County has been focused on developing the life sciences sector for years, and DiaTech’s investment in our community is a direct result of hard work by a number of community leaders.”

“Health care is one of the foundational economic sectors in Williamson County,” Williamson County Chamber of Commerce President and CEO Matt Largen said. “DiaTech’s laboratory operation will help us diversify the health care sector by capturing the increasingly important research and development component. I am thankful DiaTech selected Williamson County and look forward to partnering with them to grow their presence here.”

The 39 new jobs include technical staffing positions for medical technologists with extensive experience in isolation, purification and culturing of tumor cells from human tissues, diagnostic multiparameter flow cytometry, and histology and immunohistochemistry. To apply, please forward your resume to career@diatech-oncology.com.

About DiaTech Oncology
DiaTech Oncology, based in Nashville, Tenn., is a life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. The only test on the market that evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective, the MiCK assay has successfully tested all types of cancer. The MiCK assay is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. Visit us at www.diatech-oncology.com.

nTelagent Inc. Becomes RevPoint Healthcare Technologies

Revenue cycle management company nTelagent, Inc., based in Nashville, has changed its name to RevPoint Healthcare Technologies, officials announced today.

Since 2005, RevPoint has provided hospitals and clinics across the country with an advanced revenue cycle management solution that helps healthcare providers and their patients navigate a complex reimbursement environment, focusing on enhancing collections at the point of service. With an average return on investment of 3:1, RevPoint’s SmartCycle™ technology also leads to a better patient experience and increased employee performance and satisfaction.

“Our new name says a lot about us,” said Hal Andrews, Chairman, President and Chief Executive Officer. “We serve clients by partnering with them and pointing them in the right direction to increase revenue.”

Andrews says hospitals are increasingly focused on managing the “patient portion” of the revenue cycle, especially in the face of uncertainty related to health insurance exchanges that are scheduled to begin enrolling individuals on Oct. 1, 2013.

“Our name is changing, but our mission is not,” Andrews said. “We remain dedicated to helping providers thrive financially and better care for patients in this quickly evolving healthcare environment.”

By guiding employees through each patient encounter in real time, SmartCycle™ leads to fast, simple and accurate account resolution for all patients at the point of service, whether patients are insured, uninsured, underinsured and/or qualify for financial assistance.

“Our product is a proven solution and an invaluable tool for healthcare providers today,” said Chief Product Strategy Officer Irene Barron. “It simplifies the payment process, increases revenue collections and makes patients and employees happier. At the end of the day, it helps our clients succeed.”

To learn more about RevPoint visit www.revpointhealth.com.

About RevPoint Healthcare Technologies
RevPoint is a revenue cycle management company with a proven solution to increase point-ofservice collections, enhance employee performance and improve patient satisfaction. Our technology leads to fast, simple and accurate resolution of all patient accounts at the point of service, whether patients are insured, uninsured, underinsured and/or qualify for financial assistance. We are the leading solution for healthcare providers in need of a valuable partner at the front end of the revenue cycle.

REACH Health Named to Inc. Magazine Fastest-Growing Companies List

REACH Health, the leading provider of telemedicine software solutions, has been recognized by Inc. magazine in the 2013 Inc. 5000, an exclusive ranking of the nation’s fastest-growing private companies.

The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period. REACH Health has had tremendous growth, more than doubling revenues between 2009 and 2012.

“For 32 years, Inc. has welcomed the fastest-growing private companies in America into a very exclusive club,” said Eric Schurenberg, Editor in Chief, Inc. magazine. “Make no mistake: The Inc. 5000 was harder to get into this year than ever in its history.”

“We are very pleased to be recognized by Inc.,” said Richard Otto, President and CEO of REACH Health. “Our growth is attributable to two factors:  First, we have a terrific team at REACH Health that works very hard to ensure the high level of clinical relevance, system reliability and customer satisfaction. Second, telemedicine is being recognized as a critical software technology in helping healthcare organizations deliver timely, quality care to their patients in a cost-effective manner.”

About REACH Health
REACH Health technology powers many of the nation’s largest, fastest growing and most successful telemedicine networks, helping health systems and accountable care organizations achieve measurable improvements in their clinical, operational and financial performance. REACH Health best-in-class software solutions combine real-time audio/video technology with vital patient data, clinical workflow and documentation to overcome the traditional obstacles of time and distance. By securely connecting physicians anytime, anywhere, REACH Health technology enables remote consultations, connects patients with specialists, and supports collaboration by clinical care teams. Physicians and clinicians embrace the ease of use of a single, intuitive platform tailored to multiple specialties. REACH Health pioneered one of the nation’s first telestroke programs and remains the innovation leader, providing the most advanced clinical solutions to improve population health and address today’s demanding healthcare mandates. For more information, visit www.reachhealth.com.

PatientFocus Signs Agreement with Choice Medical

PatientFocus, a medical billing company providing enhanced patient billing services, today announced an agreement with Choice Medical, Inc., a specialty distributor of orthopedic, neurosurgical, orthotic and prosthetic product lines. The agreement will give Choice Medical patients access to Patient Focus’ suite of patient-pay account management services.

Since its 2002 launch, Choice Medical has experienced tremendous growth in orthopedic and spinal instrumentation fixation products, durable medical equipment and sports medicine bracing. The Knoxville, Tenn.-based company represents more than 80 manufacturers in 10 states with more than 100 combined accounts including hospitals, physician offices and surgery centers.

PatientFocus, based in Nashville, Tenn., focuses exclusively on patient-pay collections after insurance and before bad debt. PatientFocus functions as an extension of a billing office, providing patients with flexible, interest-free payment options without a credit check. PatientFocus manages 100 percent of patient communications, including statements, inbound and outbound telephone follow-up and online payment options.

“We’re impressed with Patient Focus’ emphasis on customer satisfaction during the billing process,” said Jennifer Monroe, Director of Billing Services of Choice Medical. “As a company, we are dedicated to successful patient communication to provide the best possible service to patients, physicians and hospitals. We’re excited to offer access to PatientFocus’ knowledgeable patient services team along with payment options that are convenient and flexible.”

PatientFocus will provide ChoiceMedical’s patients access to its financial counselors and allow patients to select payment plans online via their smartphone or computer. They can pay over time, interest-free, in a variety of ways, including check, credit card, bank draft, Health Savings Account and PayPal.

“Choice Medical is a dynamic company serving thousands of patients who require medical products associated with orthopedic, prosthetic and neurosurgical needs,” said David E. Frederiksen, PatientFocus founder and CEO. “We’re excited about working with Choice Medical because we share the same values: integrity, transparency and customer satisfaction. We look forward to helping create a patient billing process that is a positive, win-win proposition for all parties involved.”

About Choice Medical
Choice Medical, Inc., based in Knoxville, Tenn., is a specialty distributor in the orthopedic, neurosurgical, orthotic and prosthetic market. Since its 2002 launch, Choice Medical has experienced tremendous growth in orthopedic and spinal instrumentation fixation products, durable medical equipment and third-party billing programs, and spinal and sports medicine bracing. The company represents more than 80 manufacturers in 10 states with over 100 combined accounts including hospitals, physician offices and surgery centers. Choice Medical is accredited by the Accreditation Commission for Health Care. Online: http://www.choicemedinc.com

About PatientFocus
PatientFocus, Inc., based in Nashville, Tenn., is a medical billing company focused exclusively on self-pay and patient-pay accounts after insurance and before bad debt collections. PatientFocus functions as an outsourced extension of its clients’ billing offices, providing every patient flexible, interest-free payment options without a credit check. PatientFocus manages 100 percent of patient communications, including statements, inbound and outbound telephone follow-up and online payment options. PatientFocus is experiencing rapid growth and has more than tripled clients in the past year. Clients include many leading national healthcare corporations, such as Anesthesia Medical Group, e+CancerCare and Optimal Radiology. Online: www.patientfocus.com

REACH Health Secures $7.4 Million in Funding

REACH Health, Inc., the leading provider of telemedicine software solutions, announced today that it has secured $7.4 million in funding. The investment firms of Buckhead Investment Partners, Council Capital and C&B Capital participated in a $4.4 million equity financing. In addition, REACH Health secured up to an additional $3 million in debt from Silicon Valley Bank.

The funding from these nationally recognized healthcare investors will enable REACH to maximize growth opportunities as more health systems implement REACH’s comprehensive telemedicine solutions to improve outcomes and reduce costs. The capital will also support the company’s continued rollout of the REACH Access platform for specialties such as neurology, cardiology, pulmonology, psychiatry and stroke.

Clinically driven REACH Health telemedicine solutions integrate real-time audio/video technology with vital patient information, images, workflow and documentation. The company’s multidiscipline workflows meet the needs of a wide range of specialties while allowing healthcare systems to invest in a single technology platform.

“We are pleased to complete this round of funding and believe that the commitment of our financial partners further validates the significant growth opportunities ahead for REACH Health,” said Richard Otto, President and CEO of REACH Health. “Telemedicine is playing an increasingly important role for healthcare systems, hospitals and accountable care organizations that need to deliver timely, quality care to their patients in a cost-effective manner.”

REACH Health was a pioneer of telestroke, and today remains at the forefront of the industry, with technology solutions that help health systems achieve measurable improvements in their clinical, operational and financial performance. By providing better access to physicians and specialists – regardless of location or time – health systems can increase patient satisfaction and quality of life while significantly impacting outcomes.

About REACH Health
REACH Health technology powers many of the nation’s largest, fastest growing and most successful telemedicine networks, helping health systems and accountable care organizations achieve measurable improvements in their clinical, operational and financial performance. REACH Health best-in-class software solutions combine real-time audio/video technology with vital patient data, clinical workflow and documentation to overcome the traditional obstacles of time and distance. By securely connecting physicians anytime, anywhere, REACH Health technology enables remote consultations, connects patients with specialists, and supports collaboration by clinical care teams. Physicians and clinicians embrace the ease of use of a single, intuitive platform tailored to multiple specialties. REACH Health pioneered one of the nation’s first telestroke programs and remains the innovation leader, providing the most advanced clinical solutions to improve population health and address today’s demanding healthcare mandates. For more information, visit www.reachhealth.com.

DiaTech Oncology Receives New York State Clinical Laboratory Permit

DiaTech Oncology, a life sciences and clinical pathology laboratory company based in Nashville, Tenn., today announced that the company has received a Clinical Laboratory Permit from the New York State Department of Health (NYS DOH). DiaTech’s  predictive assay test — which  guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient — is  now available to patients and physicians in all 50 states.

In clinical trials and published research, use of DiaTech Oncology’s test — the MiCK® assay or Correct Chemo® — has consistently shown an increase in complete or partial response rates, longer time to relapse and a trend to longer survival times for more than 50 types of cancers, including lung, breast, colorectal, stomach, prostate, liver, ovarian, esophageal, bladder, non-Hodgkin lymphoma, leukemia and other cancers.
“New York State has the most stringent requirements for laboratory test approval in the United States,” says Garry Latimer, DiaTech CEO. “Receiving this permit is great news for cancer patients. It affirms that our CAP-accredited, CLIA-certified laboratory meets the highest standards for accurate and reliable clinical laboratory services.”
”DiaTech’s predictive assay — the only test on the market that guides the treating oncologist to the most effective chemotherapy for inducing apoptotic cell death in the malignant cells of a particular cancer patient — is now available to more cancer patients and oncologists than ever before,” states Dr. Cary Presant, DiaTech Chief Medical Officer. “Our clinical studies consistently reveal that patients treated with MiCK assay-guided chemotherapy demonstrate longer survival times and lower costs, and our studies are continuing to produce unexpected new leads for innovative therapeutic strategies.”
DiaTech’s patented MiCK assay measures apoptosis, or cell death, in the cancer cells of chemotherapy patients. Tumor cells are exposed to multiple doses of several chemotherapeutic drugs, either as single drugs or combinations. An algorithm monitors and computes the amount of cell death and determines a drug sensitivity “score” of the patients’ tumor cells.
 
About DiaTech Oncology
DiaTech Oncology, based in Nashville, Tenn., is a life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. The only test on the market that evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective, the MiCK assay has successfully tested all types of cancer. The MiCK assay is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. Online: www.diatech-oncology.com

DiaTech Oncology Announces Capital Raise of $18 Million

DiaTech Oncology, a privately held life sciences and clinical pathology laboratory company offering patient-specific cancer testing, announced today that it has completed an $18 million equity capital raise.

DiaTech Oncology’s predictive test – the MiCK® assay or Correct Chemo™ – reveals which chemotherapy agent, or combination of agents, will kill the cancer cells of a specific, individual patient prior to treatment. DiaTech’s test helps oncologists determine the best treatment plans for their patients and has shown significantly positive results and improved survival for more than 50 different types of cancer.

The proceeds of the offering will primarily be used to develop additional laboratories to support DiaTech’s rapid growth, as well as to expand relationships with payors and research programs with institutional and academic partners.

“We are excited to announce this funding and pleased with the investor response to our offering,” says Andy Miller, DiaTech Chairman. “This capital provides us the opportunity to accelerate our efforts in serving patients and physicians on the front line in the fight against cancer.”

The patented MiCK assay measures apoptosis, or cell death, in the cancer cells of chemotherapy patients. Tumor cells are exposed to multiple doses of several chemotherapeutic drugs, either as single drugs or combinations. An algorithm monitors and computes the amount of cell death and determines a drug effectiveness “score” for each drug and combination against the patients’ own tumor cells. The oncologist then recommends the drugs or combinations that are most effective in killing the cancer.

“DiaTech’s test is the only test on the market that reveals to the treating oncologist the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient. As our clinical studies show, DiaTech’s test can guide therapy in individual patients, leading to longer survival times and lower cost,” says Cary Presant, M.D., DiaTech Chief Medical Officer.

About DiaTech Oncology
DiaTech Oncology, based in Nashville, Tenn., is a life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. The only test on the market that evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective, the MiCK assay has successfully tested all types of cancer. The MiCK assay is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. Online: www.diatech-oncology.com

REACH Health Powers Telemedicine Stroke Program at Premier Health

Premier Health has launched its new Telemedicine Stroke Network using REACH Health telemedicine technology solutions. The first two hospitals in the stroke network initiated remote stroke consultations in early April, with other hospital and emergency center locations being added throughout the year.

Telemedicine enables physicians specifically trained in acute stroke care to be electronically transported to the patient’s bedside instantly. Such timely interactions with the family, ER physician and most importantly, the patient, allow for a thorough and rapid patient evaluation.
“We are delighted that Premier Health chose REACH Health as the platform for their telemedicine stroke network,” said Richard Otto, President and CEO of REACH Health. “A clinically driven telemedicine solution is much more than a piece of equipment – it streamlines the provision of specialty care and eliminates the traditional barriers of time and distance, so health systems can leverage their resources to deliver quality health care when and where it is needed.”

REACH Health’s telemedicine solutions integrate real-time audio/video technology with vital patient information, images, workflow and documentation. The company’s multidiscipline workflows meet the needs of a wide range of specialties while allowing healthcare systems to invest in a single technology platform.
 
About Premier Health
Based in Dayton, Ohio, Premier Health (www.premierhealth.com) provides services to patients throughout a nine-county region, and its mission is to build healthier communities.  The health system operates four hospitals, Miami Valley Hospital, Good Samaritan Hospital, Atrium Medical Center and Upper Valley Medical Center. In addition, the health system offers a large primary and specialty care network, along with home health services.  With over 14,000 employees and 2,300 physicians, the health system is the second largest employer in the region and is the largest health care system in Southwest Ohio.

About REACH Health
REACH Health technology powers many of the nation’s largest, fastest growing and most successful telemedicine networks, helping health systems and accountable care organizations achieve measurable improvements in their clinical, operational and financial performance. REACH Health best-in-class software solutions combine real-time audio/video technology with vital patient data, clinical workflow and documentation to overcome the traditional obstacles of time and distance. By securely connecting physicians anytime, anywhere, REACH Health technology enables remote consultations, connects patients with specialists, and supports collaboration by clinical care teams. Physicians and clinicians embrace the ease of a single, intuitive platform tailored to multiple specialties. REACH Health pioneered one of the nation’s first telestroke programs and remains the innovation leader, providing the most advanced clinical solutions to improve population health and address today’s demanding healthcare mandates. For more information, visit www.reachhealth.com.

REACH Health Announces Strategic Partnership with Rubbermaid Healthcare

REACH Health, Inc., the leading provider of telemedicine software solutions, and Rubbermaid Healthcare, the premier provider of telemedicine carts for healthcare facilities, have entered into a strategic partnership to offer an all-encompassing workflow management system to the telemedicine marketplace.

Clinically driven REACH Health telemedicine technology software solutions combine real-time audio/video technology with vital patient information, images, workflow and critical documentation. Mobile telemedicine devices connect the point-of-care to consulting physicians so they can examine patients remotely and view clinical information.

“We are delighted to partner with Rubbermaid Healthcare and offer their telemedicine endpoints and other capabilities to support health systems and ACOs in improving their clinical, operational and financial performance,” said Richard Otto, President and CEO of REACH Health. “The Rubbermaid and REACH Health brands are synonymous with quality, reliability and exceeding customer expectations.”

Rubbermaid’s best-in-class mobile telemedicine carts optimize the benefits of REACH Health’s cutting edge software solutions. In addition, Rubbermaid’s extensive network of service technicians will provide support. Rubbermaid telemedicine endpoints are engineered to Rubbermaid Healthcare’s highest quality standards with ease of use and interoperability.

“We very much believe that for telemedicine to transform how we deliver healthcare and fulfill the promises of virtual care, we must collaborate. This partnership will help to accelerate the creation of relevant telemedicine solutions by providing health systems with the highest quality mobile carts that have been seamlessly integrated with the leading software technology,” said David Pirkle, President of Rubbermaid Healthcare.

The combined focus of both companies on the future of telemedicine will help to provide healthcare systems with the advanced technologies they need as they progress on the pathway of the continuum of care.

About REACH Health
REACH Health technology powers many of the nation’s largest, fastest growing and most successful telemedicine networks, helping health systems and accountable care organizations achieve measurable improvements in their clinical, operational and financial performance. REACH Health best-in-class software solutions combine real-time audio/video technology with vital patient data, clinical workflow and documentation to overcome the traditional obstacles of time and distance. By securely connecting physicians anytime, anywhere, REACH Health technology enables remote consultations, connects patients with specialists, and supports collaboration by clinical care teams. Physicians and clinicians embrace the ease of use of a single, intuitive platform tailored to multiple specialties. REACH Health pioneered one of the nation’s first telestroke programs and remains the innovation leader, providing the most advanced clinical solutions to improve population health and address today’s demanding healthcare mandates. For more information, visit www.reachhealth.com.

About Rubbermaid Healthcare
Rubbermaid Healthcare is the premier provider of medication carts, wall-mounted workstations, mobile computing solutions and telemedicine carts for healthcare facilities striving to enhance patient care, safety and staff productivity. Product development focuses on providing caregiver workflow advantages and improving the integration and acceptance of technology into the patient care process. www.rubbermaidhealthcare.com